Drug & intervention

iloprost

RxCUI 40138

Clinical trials17
Recruiting0
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Iloprost

Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues. Iloprost is a prostacyclin mimetic. For pulmonary arterial hypertension, iloprost is given via inhalation. Iloprost works by opening (dilating) the blood vessels to allow the blood to flow through them. It was developed by the pharmaceutical company Schering AG and is marketed by Bayer Schering Pharma AG in the European Union and by Actelion Pharmaceuticals in the US.

Read on Wikipedia ↗ Wikidata Q20817139 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

17 shown
Oral Iloprost for the Prevention of Lung Cancer In Former SmokersNCT05411107 · 2024-06-01
WITHDRAWN
Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection FractionNCT03620526 · 2017-11-29
UNKNOWN
Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial HypertensionNCT03365479 · 2017-05-01
COMPLETED
Iloprost in Preventing Lung Cancer in Former SmokersNCT02237183 · 2015-11-05
COMPLETED
Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung VentilationNCT02784899 · 2015-10-08
COMPLETED
Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension PatientsNCT01712997 · 2012-09-01
UNKNOWN
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)NCT01437878 · 2012-03-01
TERMINATED
Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart DiseaseNCT01319045 · 2011-06-01
TERMINATED
Iloprost Effects on Gas Exchange and Pulmonary MechanicsNCT01274481 · 2011-03-01
COMPLETED
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial HypertensionNCT01054105 · 2010-10-01
COMPLETED
Inhaled Iloprost in Mild AsthmaNCT01209533 · 2010-09-01
COMPLETED
Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care PatientsNCT00981591 · 2009-09-01
WITHDRAWN
Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial HypertensionNCT00709098 · 2008-09-01
COMPLETED
Inhaled Iloprost for Sarcoidosis-associated Pulmonary HypertensionNCT00403650 · 2006-11-01
COMPLETED
Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)NCT00561223 · 2006-11-01
COMPLETED
Treatment of Elevated Arterial Pulmonary Pressure With Inhaled IloprostNCT00216931 · 2006-05-01
WITHDRAWN
Iloprost in Preventing Lung Cancer in Patients at High Risk for This DiseaseNCT00084409 · 2001-11-01
COMPLETED

Conditions being studied

Pulmonary Arterial Hypertension6Pulmonary Hypertension5Chronic Obstructive Pulmonary Disease3Acute Respiratory Distress Syndrome2Lung Cancer2Lung Carcinoma2Acute Lung Injury1Asthma1Bronchial Epithelial Dysplasia1Congenital Heart Defects1Congenital Heart Disease1Eisenmenger's Syndrome1Heart Failure With Normal Ejection Fraction1Neonatal Hypoxic Respiratory Failure1Persistent Pulmonary Hypertension1Persistent Pulmonary Hypertension of Newborn1Precancerous Condition1Respiratory Distress Syndrome1Sarcoidosis1Stage I Lung Cancer AJCC v81

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.